The unaffordable cost was found to be a significant barrier to insulin therapy and a factor favouring PIR in Nigeria with an average monthly cost of $39.00.26,27,28 The lack of state subsidies, the grouping of patients in association with diabetes and a policy of diabetes control in the face of the progress of the pharmaceutical industry are all factors in favour of the PIR. The gene discussed is INS; the disease is diabetes mellitus.